Cidara Therapeutics, Inc.
CDTXDelisted Jan 7, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001610618
Cidara Therapeutics, Inc. was delisted on Jan 7, 2026; its insiders filed their last Form 4 on Jan 9, 2026; 255 institutions reported holding it in 13F filings for Q4 2025, worth $7.36B in total; 3 superinvestors held it, including Maverick Capital and Soros Fund Management.
Q3 2023 vs. Q2 2023
How the institutions holding Cidara Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 52 | 52 | 0 |
| Shares | 26.3M | 24.1M | −2.18M (−8.3%) |
| Value | $29.7M | $22.7M | −$6.99M (−23.5%) |
New holders (7)
Institutions that held Cidara Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Gsa Capital Partners LLP | 136,974 | $129.0K | 0.01% |
| Pale Fire Capital SE | 54,356 | $51.2K | 0.01% |
| Flagship Harbor Advisors, LLC | 30,011 | $28.3K | 0.00% |
| Mercer Global Advisors Inc | 28,750 | $27.0K | 0.00% |
| Virtu Financial LLC | 19,064 | $18.0K | 0.00% |
| Qube Research & Technologies Ltd | 3,454 | $3.25K | 0.00% |
| Cubist Systematic Strategies, LLC | 89 | $84 | 0.00% |
Sold out (7)
Institutions that held Cidara Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Parkman Healthcare Partners LLC | 136,011 | $153.7K |
| Millennium Management LLC | 119,190 | $134.7K |
| Marshall Wace, LLP | 89,315 | $100.9K |
| Vontobel Holding Ltd. | 82,185 | $92.9K |
| Kestra Advisory Services, LLC | 76,500 | $86.4K |
| Susquehanna International Group, LLP | 24,251 | $27.4K |
| Group One Trading, L.P. | 6,646 | $7.51K |